Telesis Bio Valuation
| TBIODelisted Stock | USD 2.98 0.02 0.67% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Telesis Bio has a current Real Value of $2.72 per share. The regular price of the company is $2.98. Our model measures the value of Telesis Bio from inspecting the company fundamentals such as Return On Equity of -1.48, operating margin of (6.76) %, and Shares Outstanding of 1.77 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Telesis Bio's price fluctuation is very steady at this time. Calculation of the real value of Telesis Bio is based on 3 months time horizon. Increasing Telesis Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Telesis Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Telesis Pink Sheet. However, Telesis Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.98 | Real 2.72 | Hype 2.98 |
The intrinsic value of Telesis Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Telesis Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Telesis Bio helps investors to forecast how Telesis pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telesis Bio more accurately as focusing exclusively on Telesis Bio's fundamentals will not take into account other important factors: Telesis Bio Total Value Analysis
Telesis Bio is at this time forecasted to have valuation of 61.1 M with market capitalization of 5.73 M, debt of 34.38 M, and cash on hands of 654.75 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Telesis Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
61.1 M | 5.73 M | 34.38 M | 654.75 M |
Telesis Bio Investor Information
About 38.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Telesis Bio recorded a loss per share of 30.42. The entity had not issued any dividends in recent years. The firm had 1:18 split on the 9th of May 2024. Based on the analysis of Telesis Bio's profitability, liquidity, and operating efficiency, Telesis Bio is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Telesis Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Telesis Bio has an asset utilization ratio of 39.07 percent. This suggests that the Company is making $0.39 for each dollar of assets. An increasing asset utilization means that Telesis Bio is more efficient with each dollar of assets it utilizes for everyday operations.Telesis Bio Ownership Allocation
Telesis Bio maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Telesis Bio Profitability Analysis
The company reported the previous year's revenue of 27.51 M. Net Loss for the year was (47.72 M) with profit before overhead, payroll, taxes, and interest of 15.6 M.About Telesis Bio Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Telesis Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Telesis Bio based exclusively on its fundamental and basic technical indicators. By analyzing Telesis Bio's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Telesis Bio's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Telesis Bio. We calculate exposure to Telesis Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Telesis Bio's related companies.Translate Bio, Inc., a clinical-stage messenger RNA therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. Translate Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.
8 Steps to conduct Telesis Bio's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Telesis Bio's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Telesis Bio's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Telesis Bio's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Telesis Bio's revenue streams: Identify Telesis Bio's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Telesis Bio's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Telesis Bio's growth potential: Evaluate Telesis Bio's management, business model, and growth potential.
- Determine Telesis Bio's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Telesis Bio's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Telesis Bio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 29.8 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Telesis Pink Sheet
If you are still planning to invest in Telesis Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Telesis Bio's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |